Nuvation Bio (NUVB) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Nuvation Bio (NUVB) over the past year, losing 4.7% versus a loss of 45.6%. Over five years, TYRA leads with a -15.7% price change compared with -53.5% for NUVB. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.34 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | TYRA |
|---|---|---|
| Share price | $3.80 | $20.12 |
| Market cap | $1.34B | $1.39B |
| 1-day change | -0.26% | +1.98% |
| YTD return | -57.59% | -23.47% |
| 1-year return | -45.64% | -4.73% |
| 5-year return | -53.49% | -15.71% |
| EPS (TTM) | $-0.39 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.90M | — |
| Revenue growth (YoY) | +698.96% | — |
| Net income (latest FY) | $-204.63M | $-119.95M |
| Operating margin | -338.72% | — |
| Net margin | -325.31% | — |
| 52-week high | $9.75 | $40.65 |
| 52-week low | $3.71 | $18.25 |
| Distance from 52-week high | -61.03% | -50.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +227.63% | +135.83% |
| Average volume | 5.24M | 852.56K |
| Shares outstanding | 352.02M | 69.08M |
| Employees | 310 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed NUVB by 40.9 percentage points over the past year.
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
NUVB vs TYRA FAQ
Which is bigger, Nuvation Bio or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.34B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, NUVB or TYRA?
TYRA returned -4.73% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.